Kiniksa reports Q2 EPS 23c, consensus 26c

Reports Q2 revenue $156.8M, consensus $146.42M. “Our robust commercial performance in the second quarter was driven by expanding ARCALYST penetration across the recurrent pericarditis population, supported by growth among both new and repeat prescribers. For 2025, we’ve raised our ARCALYST net sales guidance to between $625 and $640 million from between $590 and $605 million. This represents 52% year-over-year growth at the midpoint, highlighting the ongoing strength of the ARCALYST commercialization more than four years after launch,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa (KNSA). “In addition, we are excited that the Phase 2 dose-focusing portion of the pivotal Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis is now recruiting. We expect data from this part of the study in the second half of 2026 and potential market entry in the 2028/2029 timeframe.”